Hypertension is characterized by unclear etiology, prolonged disease duration, and incurability, ranking highest in prevalence among metabolic disorders. To alleviate patient burden, hypertension health management (HHM) was incorporated into National Essential Public Health Services Program (NEPHSP). However, patient follow-up rates remain substantially below expected levels. Digital therapeutics (DTx) deliver evidence-based therapeutic interventions through high-quality software programs to prevent, manage, or treat hypertension. This approach significantly enhances clinician-patient communication frequency and optimizes healthcare resource utilization efficiency. This study examines hypertension DTx products within the Digital Therapeutics Alliance (DTA) product library and published randomized controlled trials (RCTs) to explore application prospects in China. Findings indicate that China should draw on international DTx experiences for HHM, leverage socio-environmental factors to enhance stakeholder acceptance of DTx concepts, establish regulatory frameworks aligned with product characteristics, strengthen enterprise's research and development capabilities, and accelerate DTx advancement in hypertension management.

高血压具有病因不明确、病程较长、无法完全根治等特点，其患病率居于代谢性疾病首位。为了减轻患者的疾病负担，高血压健康管理从2009年起被纳入国家基本公共卫生服务项目，然而高血压患者的随访率远低于预期水平。数字疗法通过高质量的软件程序提供循证治疗干预措施，从而预防、管理或治疗高血压，对于增加医患之间的沟通频次，提高卫生资源利用效率具有重要意义。本文梳理国际数字疗法联盟产品库以及当前文献数据库中已发表随机对照试验研究结果的高血压数字疗法产品，探讨我国未来高血压数字疗法产品的应用前景。研究提示我国应吸取国际高血压数字疗法产品在健康管理中的经验，利用社会环境提高医患双方对数字疗法理念的接受程度，从政策上建立符合产品特点的监管制度，提高企业的研发实力，推动数字疗法产品在高血压健康管理领域的发展。